<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711917</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinMUGH</org_study_id>
    <secondary_id>Narina Goulvaden</secondary_id>
    <nct_id>NCT02711917</nct_id>
  </id_info>
  <brief_title>Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane</brief_title>
  <official_title>Consumption of Rocuronium Under Etomidate-based Versus Propofol-based Maintenance of General Anesthesia Under Different Concentration of Sevoflurane- BIS Guided Clinical Trial in a Closed Loop Infusion System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different concentration of sevoflurane was given to maintain anesthesia. The dose of propofol
      to maintain BIS between 40-60 and the consumption of rocuronium was recorded and evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 age group of patients was selected, 40-60 years and above 60 years. Maintenance of
      anesthesia was carried out using different concentration of Sevoflurane, ie MAC 0.5, 0.75 and
      1.0. Bis value was kept between 40-60 and the dose of propofol required was recorded.
      Rocuronium infusion given in a close loop infusion system for different group was tabulated.
      The results was then analysed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>consumption of propofol</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Propofol, Etomidate, Rocuronium consumption under specific concentration of sevoflurane keeping BIS between 40-60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery Index</measure>
    <time_frame>Intraoperative</time_frame>
    <description>T25%-T75%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Time from starting infusion of Rocuronium at induction till T&lt;10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sevoflurane time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Time from starting sevoflurane till end tidal concentration is reached</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Neuromuscular Monitoring</condition>
  <arm_group>
    <arm_group_label>SP1- sevoflurane MAC 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP2- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP3 -Sevoflurane MAC 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP4- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP5- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SE1- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SE2- Sevoflurane 0.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SE3- Sevoflurane MAC 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAC 0.5</intervention_name>
    <description>0.5 MAC Sevoflurane</description>
    <arm_group_label>SP1- sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SP4- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SE1- Sevoflurane MAC 0.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAC 0.75</intervention_name>
    <description>0.75 MAC Sevoflurane</description>
    <arm_group_label>SP2- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_label>SP5- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_label>SE2- Sevoflurane 0.75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAC 1.0</intervention_name>
    <description>1.0 MAC Sevoflurane</description>
    <arm_group_label>SP3 -Sevoflurane MAC 1.0</arm_group_label>
    <arm_group_label>SE3- Sevoflurane MAC 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol consumption</description>
    <arm_group_label>SP1- sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SP2- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_label>SP3 -Sevoflurane MAC 1.0</arm_group_label>
    <arm_group_label>SP4- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SP5- Sevoflurane MAC 0.75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>Etomidate consumption</description>
    <arm_group_label>SE1- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SE2- Sevoflurane 0.75</arm_group_label>
    <arm_group_label>SE3- Sevoflurane MAC 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Consumption of Rocuronium</description>
    <arm_group_label>SP1- sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SP2- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_label>SP3 -Sevoflurane MAC 1.0</arm_group_label>
    <arm_group_label>SP4- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SP5- Sevoflurane MAC 0.75</arm_group_label>
    <arm_group_label>SE1- Sevoflurane MAC 0.5</arm_group_label>
    <arm_group_label>SE2- Sevoflurane 0.75</arm_group_label>
    <arm_group_label>SE3- Sevoflurane MAC 1.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &lt; 30

          -  elective Gynaecological/abdominal/urological surgery

          -  Operation time &lt; 3hrs

          -  ASA I/II

          -  Intubated patients

        Exclusion Criteria:

          -  Coronary artery disease, cardiac, lung, hepatic and renal insufficiency

          -  Severe uncontrolled HBP

          -  Obesity (BMI &gt;30)

          -  Neuromuscular and metabolic diseases

          -  Receiving medication known to influence neuromuscular transmission

          -  Pregnancy

          -  Psychiatric disorders

          -  Allergy history to any of the drugs that will be used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guolin Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of department anesthesiology</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Guolin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Etomidate</keyword>
  <keyword>Rocuronium</keyword>
  <keyword>BIS</keyword>
  <keyword>Closed loop infusion system</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

